Abstract
Background: For once daily Long-acting muscarinic antagonists (LAMA) products, morning administration is recommended. Night-time parasympathetic activation combined with the less potent effect of LAMA closer to end of the dosing period suggests greater benefits of evening LAMA-administration.
Aims: To determine whether evening LAMA administration reduces the risk of hospitalization-requiring chronic obstructive pulmonary disease (COPD) exacerbations or all-cause mortality within one year, compared with morning dosing.
Methods: In this randomized controlled, digital platform, pragmatic trial, we used a secure digital mailbox system to invite all Danish COPD patients who used a once-daily LAMA. Danish health registers ensured complete follow-up.
Results: We enrolled 10,011 COPD patients using once-daily LAMA, randomly assigning evening (n=5,028) or morning (n=4,983) administration. In the evening-LAMA group, 245 persons (5%) met the primary outcome compared with 249 persons (5%) in the morning-LAMA group. No difference was found for the primary outcome(P=0.93). Evening LAMA reduced the risk of ICU admission(P=0.0077). There was no difference between groups in the incidence of moderate COPD exacerbation(P=0.52), NIV(P=0.51), or all-cause mortality(P=0.57).
Conclusions: Evening LAMA administration in COPD patients is safe and may be beneficial in COPD-patients at high risk of ICU admission.
Aims: To determine whether evening LAMA administration reduces the risk of hospitalization-requiring chronic obstructive pulmonary disease (COPD) exacerbations or all-cause mortality within one year, compared with morning dosing.
Methods: In this randomized controlled, digital platform, pragmatic trial, we used a secure digital mailbox system to invite all Danish COPD patients who used a once-daily LAMA. Danish health registers ensured complete follow-up.
Results: We enrolled 10,011 COPD patients using once-daily LAMA, randomly assigning evening (n=5,028) or morning (n=4,983) administration. In the evening-LAMA group, 245 persons (5%) met the primary outcome compared with 249 persons (5%) in the morning-LAMA group. No difference was found for the primary outcome(P=0.93). Evening LAMA reduced the risk of ICU admission(P=0.0077). There was no difference between groups in the incidence of moderate COPD exacerbation(P=0.52), NIV(P=0.51), or all-cause mortality(P=0.57).
Conclusions: Evening LAMA administration in COPD patients is safe and may be beneficial in COPD-patients at high risk of ICU admission.
Originalsprog | Engelsk |
---|---|
Tidsskrift | The European Respiratory Journal |
Vol/bind | 64 |
Udgave nummer | Suppl 68 |
Sider (fra-til) | PA2529 |
Antal sider | 1 |
ISSN | 0903-1936 |
DOI | |
Status | Udgivet - 2024 |